New Protein Marker Could Predict Preeclampsia Risk

Cambridge researchers have identified a protein that may serve as a reliable predictor for two of the leading causes of stillbirth and maternal‑newborn complications: preeclampsia and fetal growth restriction. The study, published in *Nature Medicine*, highlights the protein’s role in the abnormal invasion of placental cells into the uterine lining—a process that is disrupted in these conditions.

The discovery elucidates a key mechanism behind the impaired placental invasion that characterizes both preeclampsia and fetal growth restriction. By measuring levels of this protein early in pregnancy, clinicians could potentially identify women at highest risk, enabling closer monitoring and earlier intervention. The findings also open avenues for developing targeted therapies aimed at restoring normal placental function.

If translated into clinical practice, the protein‑based test could improve prenatal risk stratification and reduce the incidence of stillbirths and severe maternal and neonatal morbidity. Further research will focus on validating the marker in larger cohorts and exploring therapeutic strategies to correct the invasion defect.